Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

HCW Biologics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MIRAMAR, FLA., JULY 29, 2026 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (THE COMPANY OR HCW BIOLOGICS), (NASDAQ: HCWB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING TRANSFORMATIVE FUSION IMMUNOTHERAPEUTICS TO TREAT AUTOIMMUNE DISEASES, CANCER AND SENESCENCE-ASSOCIATED DYSPLASIA, TODAY ANNOUNCED THE PRICING OF ITS $1.6 MILLION PRIVATE PLACEMENT OFFERING (THE OFFERING) WITH A GROUP OF INVESTORS, INCLUDING OFFICERS, DIRECTORS AND AN EXISTING STOCKHOLDER OF THE COMPANY, (EACH, AND INVESTOR AND COLLECTIVELY, THE INVESTORS). PURSUANT TO A SECURITIES PURCHASE AGREEMENT ENTERED INTO WITH THE INVESTORS (THE PURCHASE AGREEMENT), THE COMPANY AGREED TO ISSUE AND SELL AN AGGREGATE OF 618,682 UNITS (THE UNITS), WITH EACH UNIT CONSISTING OF (I) ONE SHARE OF THE COMPANY'S COMMON STOCK, PAR VALUE $0.0001 PER SHARE (COMMON STOCK), OR, IN LIEU THEREOF, ONE PRE-FUNDED WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK (A PRE-FUNDED WARRANT), AND (II) THE RIGHT TO RECEIVE ONE COMMON STOCK PURCHASE WARRANT (A COMMON WARRANT) TO PURCHASE ONE SHARE OF COMMON STOCK UPON, AND SUBJECT TO, STOCKHOLDER APPROVAL OF THE ISSUANCE THEREOF.

HCW BIOLOGICS INC. ANNOUNCES PRICING OF $1.6 MILLION PRIVATE PLACEMENT OFFERING

COMPANY REQUESTED TYPE B PRE-IND MEETING WITH U.S. FDA TO DISCUSS DEVELOPMENT AND REGULATORY STRATEGY FOR ITS INVESTIGATIONAL TETRAVALENT T-CELL ENGAGER, HCW11-018B HCW11-018B HAS DEMONSTRATED POTENTIAL FOR TREATING SOLID TUMORS THAT OVEREXPRESS HUMAN TISSUE FACTOR, INCLUDING GYNECOLOGIC AND PANCREATIC CANCERS COMPANY HAS DEVELOPED A STREAMLINED, ROBUST MANUFACTURING PROCESS DESIGNED TO PRODUCE HIGH-QUALITY CGMP MATERIAL AT A LOWER COST THAN CURRENT METHODS MIRAMAR, FLA., JULY 23, 2026 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (THE COMPANY OR HCW BIOLOGICS), (NASDAQ: HCWB), A U.S.-BASED CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING TRANSFORMATIVE FUSION IMMUNOTHERAPEUTICS TO TREAT DISEASES PROMOTED BY CHRONIC INFLAMMATION, FOCUSING ON AUTOIMMUNE DISORDERS AND OTHER INFLAMMATORY DISEASES, CANCER AND SENESCENCE-ASSOCIATED DYSPLASIA, TODAY ANNOUNCED THAT IT HAS REQUESTED A TYPE B (PRE-IND APPLICATION) MEETING WITH THE U.S. FDA TO DISCUSS THE DEVELOPMENT AND REGULATORY STRATEGY FOR ITS INVESTIGATIONAL LEAD PRODUCT CANDIDATE, HCW11-018B, A TETRAVALENT T-CELL ENGAGER (TCE) CONSTRUCTED WITH THE COMPANY'S PROPRIETARY TRBC DRUG DEVELOPMENT PLATFORM.

HCW BIOLOGICS REACHES MILESTONESFOR ITS PROPRIETARY TETRAVALENT SECOND-GENERATION T-CELL ENGAGER PROGRAM ON TRACK TO INITIATE CLINICAL TRIALS IN FIRST HALF 2027

MIRAMAR, FLA., JUNE 30, 2026 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (THE COMPANY OR HCW BIOLOGICS) (NASDAQ: HCWB), A U.S.-BASED CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING TRANSFORMATIVE FUSION IMMUNOTHERAPEUTICS TO SUPPORT OR TREAT DISEASES PROMOTED BY CHRONIC INFLAMMATION, FOCUSING ON AUTOIMMUNE DISORDERS AND OTHER INFLAMMATORY DISEASES, CANCER AND SENESCENCE-ASSOCIATED DYSPLASIA, TODAY REPORTED THAT, ON JUNE 29, 2026, THE NASDAQ HEARINGS PANEL (THE PANEL) OF THE NASDAQ STOCK MARKET LLC (NASDAQ OR THE EXCHANGE) FOUND THAT THE COMPANY REGAINED COMPLIANCE WITH LISTING RULE 5550(A)(2), THE BID PRICE RULE, PER THE TERMS SET FORTH IN THE PANEL'S DECISION LETTER DATED MAY 29, 2026, AS AMENDED, AND IS SUBJECT TO A MANDATORY MONITORING PERIOD THROUGH JUNE 17, 2027.

HCW BIOLOGICS REGAINED COMPLIANCE WITH BID PRICE RULE PER NASDAQ COMPLIANCE LETTER

COMPANY COMPLETED 28 CONSECUTIVE TRADING DAYS ABOVE $1.00 PER SHARE ON JUNE 25, 2026 REVERSE STOCK SPLIT EFFECTUATED TO ENSURE ONGOING COMPLIANCE WITH THE BID PRICE RULE AND ADDITIONAL REQUIREMENTS FROM NASDAQ HEARINGS PANEL MIRAMAR, FLA., JUNE 26, 2026 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (THE COMPANY OR HCW BIOLOGICS) (NASDAQ: HCWB), A U.S.-BASED CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING TRANSFORMATIVE FUSION IMMUNOTHERAPEUTICS TO SUPPORT OR TREAT DISEASES PROMOTED BY CHRONIC INFLAMMATION, FOCUSING ON AUTOIMMUNE DISORDERS AND OTHER INFLAMMATORY DISEASES, CANCER AND SENESCENCE-ASSOCIATED DYSPLASIA, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED A 1-FOR-6 REVERSE STOCK SPLIT OF THE COMPANY'S COMMON STOCK, PAR VALUE $0.0001 (COMMON STOCK), WHICH WILL BE EFFECTIVE AT 12:01 A.M.

HCW BIOLOGICS ANNOUNCES 1-FOR-6 REVERSE STOCK SPLIT EFFECTIVE ON JUNE 30, 2026

POTENTIALLY BEST-IN-CLASS IL-2 BASED TREATMENT FOR AUTOIMMUNE DISEASES BY EXPANDING AND ACTIVATING REGULATORY T CELLS READOUT FOR DOSE-ESCALATING CLINICAL STUDY FOR FIRST TWO DOSE COHORTS ALL PARTICIPANTS IN SECOND DOSE COHORT AT THE DOSE LEVEL OF 3 MICROGRAMS/KG BODY WEIGHT SHOWED POSITIVE CLINICAL RESPONSE AFTER SINGLE DOSE ADMINISTRATION WELL TOLERATED, WITH NO DOSE-LIMITING TOXICITIES OR SIGNIFICANT KNOWN IL-2-TREATMENT-RELATED ADVERSE EFFECTS, INCLUDING NO REPORTED INCIDENCE OF CAPILLARY LEAK, CYTOKINE RELEASE SYNDROME, OR INCREASE IN BLOOD EOSINOPHIL COUNTS HCW BIOLOGICS PROJECTS TO ESTABLISH THE RECOMMENDED PHASE 2 DOSE BY YEAR END 2026 MIRAMAR, FLA., JUNE 16, 2026 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (HCWB OR THE COMPANY) (NASDAQ: HCWB), A U.S.-BASED CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING TRANSFORMATIVE FUSION IMMUNOTHERAPEUTICS TO SUPPORT OR TREAT DISEASES PROMOTED BY CHRONIC INFLAMMATION, FOCUSING ON AUTOIMMUNE DISORDERS AND OTHER INFLAMMATORY DISEASES, CANCER AND SENESCENCE-ASSOCIATED DYSPLASIA, TODAY ANNOUNCED A POSITIVE PRELIMINARY HUMAN DATA READOUT FOR THE FIRST TWO DOSE COHORTS FROM ITS DOSE-ESCALATING PHASE 1 CLINICAL TRIAL OF HCW9302, AN IL-2 BASED FUSION IMMUNOTHERAPEUTIC, IN PATIENTS WITH ALOPECIA AREATA.

HCW BIOLOGICS ANNOUNCES POSITIVE RESULTS FOR PRELIMINARY HUMAN DATA READOUT FOR PHASE 1 CLINICAL TRIAL EVALUATING IL-2 BASED FUSION IMMUNOTHERAPEUTIC, HCW9302 MONOTHERAPY, IN ALOPECIA AREATA

POSITIONS THE COMPANY TO PARTICIPATE IN FAST-GROWING, MULTI-BILLION-DOLLAR CAR-T IMMUNOTHERAPY MARKET RECENTLY PUBLISHED DATA SUGGEST THAT HCW9206 MAY REDUCE CAR-T PRODUCTION COSTS AND IMPROVE THERAPEUTIC EFFICACIES, WITH THE POTENTIAL TO SUPPORT CURATIVE OUTCOMES COMPANY PLANS TO COMMERCIALIZE THE REAGENTS THROUGH CORPORATE PARTNERS FOCUSED ON CAR-T AND NK-CELL THERAPIES, INCLUDING DEVELOPERS AND MANUFACTURERS MIRAMAR, FLA., MAY 27, 2026 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (THE COMPANY) (NASDAQ: HCWB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS FUSION IMMUNOTHERAPEUTICS FOR AUTOIMMUNE DISEASES, CANCER, AND SENESCENCE-ASSOCIATED DYSPLASIA, TODAY ANNOUNCED THAT IT HAS EXERCISED ITS OPTION TO REGAIN FULL EX VIVO RIGHTS TO HCW9206 AND HCW9201, TWO COMMERCIAL-READY COMPOUNDS AS REAGENTS, FROM ITS LICENSEE, WUGEN INC. WUGEN HELD EXCLUSIVE WORLDWIDE RIGHTS TO THESE TWO COMPOUNDS FOR EX VIVO, CELL-BASED THERAPY APPLICATIONS.

HCW BIOLOGICS EXERCISED OPTION TO REGAIN FULL RIGHTS FOR TWO COMMERCIAL-READY REAGENTS FROM WUGEN

NEW YORK, MAY 22, 2026 (GLOBE NEWSWIRE) -- E.F. HUTTON & CO. (E.F. HUTTON), AN INVESTMENT BANKING AND FINANCIAL ADVISORY FIRM HEADQUARTERED IN NEW YORK CITY, TODAY ANNOUNCED THAT IT ACTED AS THE SOLE PLACEMENT AGENT IN CONNECTION WITH A $4.0 MILLION PRIVATE PLACEMENT FOR HCW BIOLOGICS INC. (HCW BIOLOGICS OR THE COMPANY) (NASDAQ: HCWB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING TRANSFORMATIVE FUSION IMMUNOTHERAPEUTICS DESIGNED TO TREAT DISEASES DRIVEN BY CHRONIC INFLAMMATION, INCLUDING AUTOIMMUNE DISORDERS, CANCER, AND SENESCENCE-ASSOCIATED CONDITIONS.

E.F. HUTTON & CO. SERVES AS SOLE PLACEMENT AGENT ON HCW BIOLOGICS INC. $4.0 MILLION PRIVATE PLACEMENT

MIRAMAR, FLA., MAY 21, 2026 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (THE COMPANY OR HCW BIOLOGICS), (NASDAQ: HCWB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING TRANSFORMATIVE FUSION IMMUNOTHERAPEUTICS TO TREAT AUTOIMMUNE, CANCER AND SENESCENCE-ASSOCIATED DYSPLASIA, TODAY ANNOUNCED THE PRICING OF ITS PRIVATE PLACEMENT OF AN AGGREGATE OF 2,846,975 UNITS AT A PURCHASE PRICE OF $1.405 PER UNIT PRICED AT-THE-MARKET UNDER NASDAQ RULES TO A GROUP OF HEALTHCARE INVESTORS (THE INVESTORS). EACH UNIT CONSISTS OF (I) ONE SHARE OF COMMON STOCK AT A PURCHASE PRICE OF $1.28 PER SHARE (OR, IN LIEU THEREOF, ONE PRE-FUNDED WARRANT AT A PURCHASE PRICE OF $1.2799 PER PRE-FUNDED WARRANT WITH AN EXERCISE PRICE OF $0.0001 PER SHARE) AND (II) ONE WARRANT AT A PURCHASE PRICE OF $0.125 PER WARRANT, EACH TO PURCHASE ONE SHARE OF COMMON STOCK. THE WARRANTS WILL HAVE AN EXERCISE PRICE OF $1.28 PER SHARE, WILL BE EXERCISABLE IMMEDIATELY UPON ISSUANCE, AND WILL EXPIRE ON THE FIVE AND ONE-HALF YEAR ANNIVERSARY OF THE ORIGINAL ISSUANCE DATE. THE SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS) AND THE WARRANTS COMPRISING THE UNITS ARE IMMEDIATELY SEPARABLE AND WILL BE ISSUED SEPARATELY IN THIS OFFERING. THE CLOSING OF THE OFFERING IS EXPECTED TO OCCUR ON OR ABOUT MAY 21, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

HCW BIOLOGICS INC. ANNOUNCES PRICING OF APPROXIMATELY $4.0 MILLION PRIVATE PLACEMENT OFFERING AT-THE-MARKET UNDER NASDAQ RULES

MIRAMAR, FLA., MAY 14, 2026 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (THE COMPANY OR HCW BIOLOGICS) (NASDAQ: HCWB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING TRANSFORMATIVE FUSION IMMUNOTHERAPEUTICS TO TREAT AUTOIMMUNE DISEASE, CANCER AND SENESCENCE-ASSOCIATED DYSPLASIA, TODAY REPORTED FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS FOR THE THREE MONTHS ENDED MARCH 31, 2026.

HCW BIOLOGICS REPORTS FIRST QUARTER 2026 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS

HCW11-040 IS A PEMBROLIZUMAB-BASED FUSION IMMUNOTHERAPEUTIC THAT ACTIVATES IMMUNE CELLS AND ELIMINATES HIGH-OXYGEN INDUCED SENESCENT CELLS

HCW Biologics Inc.

HCWB

Price

Financial Reports

No items found.

Press Releases

HCW Biologics Inc.

HCWB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

HCWB